Securities Registration (section 12(b)) (8-a12b)
August 06 2020 - 4:41PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-A
FOR REGISTRATION OF CERTAIN CLASSES
OF SECURITIES
PURSUANT TO SECTION 12(b) OR (g) OF THE
SECURITIES EXCHANGE ACT OF 1934
AstraZeneca
PLC
(Exact name of registrant as specified in its charter)
England and Wales
(State or other jurisdiction of incorporation or organization)
|
Not Applicable
(I.R.S. Employer
Identification No.)
|
|
|
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge England
(Address of principal executive offices)
|
CB2 0AA
(Zip Code)
|
|
|
Securities to be registered pursuant
to Section 12(b) of the Act:
Title
of each class
to be so registered
|
Name
of each exchange on which
each class is to be registered
|
0.700% Notes due 2026
1.375% Notes due 2030
2.125% Notes due 2050
|
New York Stock Exchange
New York
Stock Exchange
New York Stock Exchange
|
If this form relates to the registration of a class of securities
pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following
box. ☒
If this form relates to the registration of a class of securities
pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following
box. ☐
If this form relates to the registration of a class of securities
concurrently with a Regulation A offering, check the following box. ☐
Securities Act registration statement or Regulation A offering
statement file number to which this form relates: 333-234586
Securities to be registered pursuant to Section 12(g) of the
Act: None.
Item 1. Description of Registrant’s Securities to
Be Registered.
The Registrant filed with the Securities
and Exchange Commission (the “Commission”) on November 8, 2019 a Registration Statement on Form F-3 (the “Registration
Statement”) relating to the Registrant’s Debt Securities. The Registration Statement was effective upon filing
with the Commission in accordance with Rule 462(e) of the Securities Act of 1933, as amended (the “Securities Act”).
On November 8, 2019, the Registrant filed a prospectus dated November 8, 2019 with the Commission pursuant to Rule 424(b)(3) under
the Securities Act (the “Prospectus”). On August 3, 2020, the Registrant filed a preliminary prospectus supplement
dated August 3, 2020 with the Commission pursuant to Rule 424(b)(2) under the Securities Act. On August 5, 2020, the Registrant
filed a final prospectus supplement dated August 3, 2020 with the Commission pursuant to Rule 424(b)(2) under the Securities Act
(the “Prospectus Supplement”). The Prospectus Supplement and the Prospectus are incorporated herein by reference
to the extent set forth below.
Reference is made to the information set
forth under the headings “Description of Debt Securities” on pages 12 through 26 and “Certain UK and
US Federal Tax Considerations” on pages 30 through 38 of the Prospectus; and to the information set forth under the heading
“Description of Notes” on pages S-13 to S-17 and “Taxation” on page S-18 of the Prospectus
Supplement, which information is incorporated herein by reference.
Item 2. Exhibits.
SIGNATURE
Pursuant to the requirements of Section
12 of the Securities Exchange Act of 1934, the Registrant has duly caused this registration statement to be signed on its behalf
by the undersigned, thereto duly authorized.
Dated: August 6, 2020
|
ASTRAZENECA PLC
|
|
(Registrant)
|
|
|
|
|
|
By:
|
/s/ Matthew Bowden
|
|
|
Name:
|
Matthew Bowden
|
|
|
Title:
|
Deputy Company Secretary
|
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Aug 2024 to Sep 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Sep 2023 to Sep 2024